Bharat Parenterals: Commencement of Commercial Supply to the U.S by Innoxel Lifesciences Private Limited, Material Subsidiary…
Bharat Parenterals (BPLPHARMA) filed a disclosure titled "Commencement of Commercial Supply to the U.S by Innoxel Lifesciences Private Limited, Material Subsidiary Company of Bharat Parenterals Limited". The company is valued at about ₹1,217 crore.
What happened
Bharat Parenterals (BPLPHARMA) filed a disclosure with the exchanges on 21 October 2026 at 01:29 PM titled "Commencement of Commercial Supply to the U.S by Innoxel Lifesciences Private Limited, Material Subsidiary Company of Bharat Parenterals Limited".
Company snapshot
Bharat Parenterals is a small-cap company, with a market value of about ₹1,217 crore.
The stock last traded at ₹1,766.3, against a 52-week range of ₹1,201.1–₹2,277.6 (22.4% below the high).
Before this filing the shares had moved +12.7% over the month. Average daily turnover over the last 20 sessions was about ₹3.59 crore.
Promoters held 67.20% at the end of Q1 FY27, up 0.03% points from the previous quarter. Foreign institutions owned 0.11% and domestic institutions 1.37%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 94 | 10 | 14.51 |
| Q2 FY26 | 42 | 2.7 | 3.96 |
| Q3 FY26 | 41 | 1.9 | 2.78 |
| Q4 FY26 | 57 | 1.4 | 2 |
| Q1 FY27 | 56 | 3.7 | 5.31 |
What history shows
BCEIE's records show 3 previous corporate update filings from the company since May 2026.
After those filings, the stock gained 5.9% on average the next trading day and was up 9.9% on average after five days (2 filings with price data).
Market-wide, 273 corporate update filings with an impact score of 50 or more saw an average next-day move of −0.2%, with 41% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 27 Aug 2026 | Corporate update | +2.2% | +2.5% |
| 20 Aug 2026 | Intimation Regarding Permission To Trade And Admission Of Equity… | +9.6% | +17.4% |
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.